Stem Cells Market Projected to Hit $32.6B by 2031, Driven by Regenerative Medicine and Manufacturing Gains
Event summary
- The global stem cells market is expected to grow from $18.9B in 2026 to $32.6B by 2031, at an 11.5% CAGR.
- Adult stem cells led the market in 2025 with 72% revenue share, followed by allogeneic therapies at 60%.
- North America held a 44% market share in 2025, while Asia-Pacific is the fastest-growing region.
- Key players include Thermo Fisher Scientific, STEMCELL Technologies, and Merck KGaA.
- Recent strategic developments include collaborations between Applied StemCell and Cellipont Bioservices, and Aspect Biosystems and Novo Nordisk.
The big picture
The stem cells market is expanding rapidly due to increasing demand for regenerative medicine and advancements in cell processing technologies. Strategic partnerships between specialized biotech firms and larger pharmaceutical players are becoming a common route to funding and scaling cell therapy development. The shift toward allogeneic, donor-derived therapies reflects an industry-wide push to move away from custom, patient-specific manufacturing toward standardized, scalable production.
What we're watching
- Manufacturing Scalability
- The pace at which companies can overcome technical and financial complexities in scaling stem cell therapies will determine market leadership.
- Regulatory Pathways
- How the industry navigates more demanding regulatory frameworks for cell-based therapies will impact approval timelines and market entry.
- Workforce Development
- The availability of skilled personnel for advanced cell processing and manufacturing operations will influence capacity expansion and growth.
Related topics